Menu
Search
|

Menu

Close
X

Neurocrine Biosciences Inc NBIX.OQ (NASDAQ Stock Exchange Global Select Market)

90.00 USD
+5.17 (+6.09%)
As of 11:49 AM EDT
chart
Previous Close 84.83
Open 86.50
Volume 142,944
3m Avg Volume 360,201
Today’s High 90.45
Today’s Low 86.50
52 Week High 126.15
52 Week Low 64.73
Shares Outstanding (mil) 90.82
Market Capitalization (mil) 7,704.37
Forward P/E 469.84
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.81 Mean rating from 16 analysts

KEY STATS

Revenue (mm, USD)
FY18
451
FY17
162
FY16
15
EPS (USD)
FY18
0.181
FY17
-1.627
FY16
-1.626
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
469.84
58.82
Price to Sales (TTM)
vs sector
17.07
9.06
Price to Book (MRQ)
vs sector
16.02
4.61
Price to Cash Flow (TTM)
vs sector
306.52
40.52
Total Debt to Equity (MRQ)
vs sector
80.81
17.60
LT Debt to Equity (MRQ)
vs sector
80.81
13.95
Return on Investment (TTM)
vs sector
2.53
12.09
Return on Equity (TTM)
vs sector
4.95
13.20

EXECUTIVE LEADERSHIP

William Rastetter
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
Kevin Gorman
Chief Executive Officer, Director, Since 2017
Salary: $575,000.00
Bonus: $345,000.00
Matthew Abernethy
Chief Financial Officer, Since 2017
Salary: $38,231.00
Bonus: $20,071.00
Eric Benevich
Chief Commercial Officer, Since 2015
Salary: $218,532.00
Bonus: $109,300.00
Haig Bozigian
Chief Development Officer, Since 2012
Salary: $381,600.00
Bonus: $190,800.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

12780 El Camino Real
SAN DIEGO   CA   92130-2042

Phone: +1858.6177600

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.

SPONSORED STORIES